###### Key questions

What is already known about this subject?
=========================================

-   Given the enormous complexity and heterogeneity of metastatic colorectal cancer (mCRC), primary tumour location has emerged as a potential prognostic and predictive factor in retrospective analyses of clinical trials in patients with KRAS/RAS-wild type (wt) mCRC treated with panitumumab-based or cetuximab-based therapies.

-   Relevant differences have been described between right-sided and left-sided mCRCs in recent studies. Further, descending and sigmoid colon cancers present differences from rectal cancer in their molecular features, treatment approaches and prognosis. *BRAF* mutations have also been associated with poorer outcomes in mCRC and described to be gradually higher from the rectum (\<2%) to the ascending colon (36%).

What does this study add?
=========================

-   This study retrospectively evaluates the impact of primary tumour location on efficacy outcomes in 261 patients with *KRAS*/*RAS* wt mCRC treated with first-line epidermal growth factor receptor inhibitor (EGFR-I) (cetuximab or panitumumab) in combination with chemotherapy. Our results clearly show that patients with tumours up to the splenic flexure (right-sided) had a significantly higher risk of death and progression compared with patients with distal tumours (left-sided).

###### Key questions

How might this impact on clinical practice?
===========================================

-   We observed similar survival outcomes when patients with rectum primary tumour location were classified accordingly.

-   According to other studies, our data also suggest that poorer efficacy outcomes might be achieved with EGFR-I in patients with right-sided tumours. The observed efficacy differences are likely related with the suggested EGFR-I -sensitive phenotype that might be more prevalent in left-sided tumours, presenting among other variables higher levels of expression of epiregulin and amphiregulin, which have been associated with enhanced response to EGFR-I. In addition, right-sided tumours have been associated with chemoresistance.

-   Our results strongly support the prognostic effect of primary tumour location in patients with KRAS/RAS-wt mCRC treated with first-line EGFR-I plus chemotherapy.

Introduction {#s1}
============

Primary tumour location has emerged as a potential prognostic and predictive factor in retrospective analyses of clinical trials in patients with *KRAS*/*RAS*-wild type (wt) metastatic colorectal cancer (mCRC) treated with panitumumab-based or cetuximab-based therapies. Better outcomes were shown in patients with left-sided tumours (those originating in the splenic flexure, descending colon, sigmoid colon or rectum) treated with epidermal growth factor receptor inhibitor (EGFR-I)-based therapies compared with chemotherapy-based or bevacizumab-based therapies.[@R1]

Relevant differences have been described in the epidemiology, pathogenesis, genetic or epigenetic features, clinical presentation and outcomes between right-sided and left-sided mCRCs.[@R9] Further, descending and sigmoid colon cancers present differences from rectal cancer in their molecular features, treatment approaches and prognosis.[@R14] *BRAF* mutations have also been associated with poorer outcomes in mCRC[@R17] and have been described to be gradually higher from the rectum (\<2%) to the ascending colon (36%).[@R13]

Given the enormous complexity and heterogeneity of mCRC, the assessment of the impact of tumour location on efficacy outcomes of different populations and settings is a paramount step towards an optimally targeted therapy. However, the stratification of patients according to tumour location has not been regarded in clinical trials.

Our aim was to retrospectively evaluate the impact of primary tumour location on efficacy outcomes in patients with *KRAS*/*RAS* wt mCRC treated with first-line EGFR-I (cetuximab or panitumumab) in combination with chemotherapy included in two phase II randomised trials conducted by the Spanish Cooperative Treatment of Digestive Tumours group.[@R18]

Methods {#s2}
=======

Study design {#s2-1}
------------

This is a retrospective, pooled analysis of two phase II, randomised, open-label, multicentre trials MACRO-2 and PLANET. Their respective study designs and treatment regimens have been previously reported.[@R18]

Patient population {#s2-2}
------------------

This retrospective analysis included all patients with *KRAS*-wt (exon 2) and *RAS*-wt (exons 2, 3 and 4 of *KRAS*/*NRAS*) mCRC who were randomised in the MACRO-2 trial and in the PLANET trial. All patients included in the PLANET trial had liver-limited disease. Patients were classified according to their primary tumour location as right-sided for patients whose tumours originated from the caecum, ascending and transverse colon up to the splenic flexure; or left-sided for patients whose tumours originated from the splenic flexure to the descending and sigmoid colon or rectum. Patients whose primary tumour locations were not available or were sited in both sides with an unknown origin were not included in the analysis. All studied variables were analysed for the pooled population according to the primary tumour location.

For the secondary analysis, patients with left-sided tumours were further classified into patients with primary tumours in the rectum and those with primary tumours from the splenic flexure to the descending and sigmoid colon.

Statistical analysis {#s2-3}
--------------------

The primary endpoint of MACRO-2 was a progression-free survival (PFS) rate at 9 months, whereas the primary endpoint of PLANET was the objective response rate (ORR) (complete response+partial response). Additionally, we analysed the following efficacy outcomes studied in the MACRO-2: overall survival (OS) and ORR. For the PLANET trial, the additional analysed outcomes were PFS and OS. Results of both confirmed and unconfirmed ORRs were reported, given that liver metastases resection was performed in some participants of the PLANET trial before radiological response confirmation.

Efficacy endpoints were analysed using descriptive statistics, 95% CIs and Kaplan-Meier plots. Survival functions were compared using the log-rank test. Cox proportional hazards model was carried out to estimate the HRs for prognostic significance for OS. Data analysis was performed using the SAS statistical package for Windows V.9.4. P values less than 0.05 were considered significant.

Results {#s3}
=======

Patients' characteristics {#s3-1}
-------------------------

A total of 270 patients were included for analysis from the MACRO-2 (n=193) and PLANET (n=77) studies. Nine patients from the MACRO-2 trial were excluded since their primary tumour location could not be determined.

Out of the evaluable *KRAS*-wt population (n=261), 52 patients (20%) presented with right-sided tumours and 209 patients (80%) presented with left-sided tumours, of which 68 (26%) were classified as rectum tumours ([figure 1A](#F1){ref-type="fig"}). Overall, 32% of patients were female, with a mean age of 60 years, and 39% had more than one metastatic site. The baseline characteristics of right-sided and left-sided populations were similar, except for a higher proportion of women (p=0.047), a lower percentage of exposure to adjuvant radiotherapy (p=0.02) and a higher number of metastatic sites (p=0.048) in patients with right-sided tumours ([table 1](#T1){ref-type="table"}).

![Patient disposition for (A) *KRAS* and (B) *RAS* wt populations. wt, wild type; mt, mutant type.](esmoopen-2019-000599f01){#F1}

###### 

Baseline characteristics in the MACRO-2 and PLANET *KRAS* wild-type pooled population according to tumour location

  ------------------------------------------------------------------------------------------------
                                            Right-sided tumour\   Left-sided tumour\   *P* value
                                            (n*=*52)              (n*=*209)            
  ----------------------------------------- --------------------- -------------------- -----------
  Sex, n (%)                                                                           0.047

   Male                                     29 (56)               148 (71)             

   Female                                   23 (44)               61 (29)              

  Median age, years (range)                 62 (37--79)           61 (32--83)          0.89

  ECOG PS, n (%)\*                                                                     0.55

   0                                        19 (45)               73 (52)              

   1                                        20 (48)               62 (44)              

   2                                        3 (7)                 6 (4)                

  Pathological T stage, n (%)                                     0.75                 

   2                                        2 (4)                 5 (2)                

   3                                        19 (37)               84 (40)              

   4                                        15 (29)               51 (24)              

   x                                        15 (29)               69 (33)              

   Missing                                  1 (2)                 0                    

  Pathological N stage, n (%)                                     0.86                 

   0                                        8 (16)                33 (16)              

   1                                        8 (16)                42 (20)              

   1b                                       0 (0)                 1 (0)                

   2                                        18 (35)               61 (29)              

   x                                        17 (33)               72 (34)              

   Missing                                  1 (2)                 0                    

  Number of affected organs, n (%)†‡        0.048                                      

   1                                        24 (47)               135 (65)             

   2                                        17 (33)               50 (24)              

   3                                        9 (18)                19 (13)              

   \>3                                      1 (2)                 3 (1)                

   Missing                                  1 (2)                 2 (1)                

  Prior surgery for primary tumour, n (%)   0.64                                       

   Yes                                      32 (63)               122 (58)             

   No                                       19 (37)               87 (42)              

   Missing                                  1 (2)                 0                    

  Prior treatment, n (%)                    6 (12)                27 (13)              1

   Chemotherapy                             6 (12)                22 (11)              0.80

   Radiotherapy                             0 (0)                 19 (9)               0.02
  ------------------------------------------------------------------------------------------------

\*ECOG PS was not registered in PLANET study.

†All patients in the PLANET study presented liver-limited disease.

‡Missing data in two patients with left-sided tumour from the MACRO-2 study.

ECOG, Eastern Cooperative Oncology Group; PS, performance status.

One hundred and eighty-one (69%) of the 261 *KRAS*-wt evaluable patients were *RAS* wt and 80 (31%) were *RAS* mutated. Thirty-three (18%) and 148 (82%) patients presented with right-sided and left-sided *RAS*-wt tumours, respectively. Forty-seven out of 68 rectum tumours presented with *RAS*-wt status ([figure 1B](#F1){ref-type="fig"}).

Impact of primary tumour location on efficacy outcomes {#s3-2}
------------------------------------------------------

ORR, median PFS and median OS were significantly greater in patients with left-sided versus right-sided tumours in both studied populations (*KRAS* and *RAS* wt) ([table 2](#T2){ref-type="table"}). In the *KRAS*-wt population, the median PFS was 7.2 months in the right-sided tumour group and 9.9 months in the left-sided tumour group (HR 0.6, 95% CI 0.4 to 0.9, p=0.016) ([figure 2A](#F2){ref-type="fig"}). The median OS was also significantly prolonged in patients with left-sided tumours (13.6 vs 27.7 months; HR 0.5, 95% CI 0.3 to 0.7, p\<0.0001) ([figure 2C](#F2){ref-type="fig"}).

###### 

Efficacy results for *KRAS* and *RAS* wt populations according to tumour location

                              *KRAS* wt            *RAS* wt                                   
  --------------------------- -------------------- --------------------- -------------------- ---------------------
  ORR (confirmed)                                                                             
   Rate, %                    25.0                 46.9                  33.3                 52.7
   OR (95% CI)                0.4 (0.2 to 0.8)                           0.5 (0.2 to 1.0)     
   P value                    0.004                                      0.044                
  PFS                                                                                         
   Median (months) (95% CI)   7.2 (4.2 to 11.1)    9.9 (9.1 to 11.7)     6.5 (3.9 to 12.6)    10.1 (9.4 to 12.1)
   HR (95% CI)                0.6 (0.4 to 0.9)                           0.6 (0.4 to 1.0)     
   P value                    0.016                                      0.044                
  OS                                                                                          
   Median (months) (95% CI)   13.6 (8.4 to 26.0)   27.7 (25.0 to 36.2)   13.6 (8.4 to 34.2)   32.8 (26.5 to 39.9)
   HR (95% CI)                0.5 (0.3 to 0.7)                           0.4 (0.3 to 0.7)     
   P value                    \<0.0001                                   0.0002               

ORR, objective response rate; OS, overall survival;PFS, progression-free survival; wt, wild type.

![Analyses of survival by primary tumour location. (A, B) Kaplan-Meier estimates of the probability of PFS in the *KRAS* and *RAS* wt populations, respectively. (C, D) Kaplan-Meier estimates of the probability of OS in the *KRAS* and *RAS* wt populations, respectively, in patients with right-sided (blue line) and left-sided (red line) tumours. OS, overall survival; PFS, progression-free survival; wt, wild type.](esmoopen-2019-000599f02){#F2}

Similarly, in the *RAS*-wt population, the median PFS and OS were 6.5 vs 10.1 months and 13.6 vs 32.8 months for patients with right-sided versus left-sided tumours, respectively (HR (PFS) 0.6, 95% CI 0.4 to 1.0, p=0.044; HR (OS) 0.4, 95% CI 0.3 to 0.7, p=0.0002) ([figure 2B, D](#F2){ref-type="fig"}).

Both *KRAS*-wt and *RAS*-wt patients with rectum tumours (n=68 (*KRAS*) and n=47 (*RAS*)) had similar efficacy results when compared with patients presenting with tumours in the descending and sigmoid colon (n=141 (*KRAS*) and n=101 (*RAS*)), both in terms of median PFS (*KRAS* wt: 9.7 vs 9.9 months, HR 0.9, 95% CI 0.6 to 1.3; *RAS* wt: 10.1 vs 10.1 months, HR 0.9, 95% CI 0.6 to 1.4) and OS (*KRAS* wt: 26.6 vs 31.5 months, HR 0.9, 95% CI 0.6 to 1.3; *RAS* wt: 32.5 vs 35.1 months, HR 1.0, 95% CI 0.6 to 1.5), respectively. Of note, a significantly lower not-confirmed ORR was observed in the rectum *RAS*-wt population (64% vs 80%; OR 0.4, 95% CI 0.2% to 0.9%) and a trend to lower confirmed ORR (45% vs 56%; OR 0.6, 95% CI 0.3% to 1.3%).

Multivariate analysis identified the left-sided location of the primary tumour (HR 0.5, 95% CI 0.3 to 0.7, p\<0.0001), more than one affected organ (HR 1.9, 95% CI 1.4 to 2.6, p*=*0.0001) and any prior surgery (HR 0.7, 95% CI 0.5 to 0.9, p=0.022) as independent prognostic factors of OS ([online supplementary table 1](#SP1){ref-type="supplementary-material"}). In the other hand, age ≥65 years, female sex and pathological n+stage were not identified as independent prognostic factors of OS ([online supplementary table 1](#SP1){ref-type="supplementary-material"}).
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Discussion {#s4}
==========

We retrospectively evaluated the effect of primary tumour location on the efficacy in 261 *KRAS*/*RAS*-wt mCRC patients treated with an EGFR-I plus chemotherapy as first line. Our results clearly show that patients with tumours up to the splenic flexure (right-sided) had a significantly higher risk of death and progression compared with patients with distal tumours (left-sided), consistent with the growing evidence reported in the literature showing the prognostic and predictive value of primary tumour location in patients with *RAS*-wt mCRC[@R1] ([table 3](#T3){ref-type="table"}). This prognostic effect has been reported to be independent of stage, race, adjuvant chemotherapy, year of study, number of participants and quality of included studies in a recent meta-analysis of 66 studies.[@R21]

###### 

Treatment effects by primary tumour location in *KRAS*/*RAS* wild-type patients in the main published studies

  --------------------------------------------------------------------------------------------------------------------------
                                Median OS (months)                           Median PFS (months)                     
  ----------------------------- -------------------------------------------- --------------------- ------- --------- -------
  CRYSTAL[@R1]                  FOLFIRI                                      15.0                  21.7    7.1       8.9

  FOLFIRI+cetuximab             18.5                                         28.7\*†               8.1     12.0\*†   

  PRIME[@R7]                    FOLFOX                                       15.4                  23.6    7.0       9.2

  FOLFOX+panitumumab            11.1                                         30.3\*†               7.5     12.9\*    

  CALGB/SWOG 80405[@R6]         FOLFOX or FOLFIRI+bevacizumab                24.5                  32.1†   9.5       11.1†

  FOLFOX or FOLFIRI+cetuximab   16.4                                         37.5†                 7.7     12.0†     

  FIRE-3[@R1]                   FOLFIRI+bevacizumab                          23.0                  28.0†   9.0       10.7

  FOLFIRI+cetuximab             18.3                                         38.3\*†               7.6     10.7†     

  PEAK[@R7]                     FOLFOX+panitumumab                           17.5                  43.4†   8.7       14.6

  FOLFOX+bevacizumab            21.0                                         32.0†                 12.6    11.5      

  Present study:\               FOLFOX or FOLFIRI+cetuximab or panitumumab   13.5                  32.7†   6.5       10.0†
  MACRO-2+PLANET                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------

\*P value statistically significant between treatments in the same tumour location.

†P value statistically significant between tumour locations (right vs left)

OS, overall survival; PFS, progression-free survival.

The negative prognostic impact of right-sided tumour location has also been demonstrated in patients treated with first-line bevacizumab, both in two retrospective cohorts and one prospective cohort, and has been found to be independent in multivariate analysis after adjusting for age, sex, race, Kohne score and prior adjuvant chemotherapy.[@R3]

The observed efficacy differences are likely related with the suggested EGFR-I-sensitive phenotype that might be more prevalent in left-sided tumours,[@R11] presenting among other variables higher levels of expression of epiregulin and amphiregulin, which have been associated with enhanced response to EGFR-I.[@R23] In addition, right-sided tumours have been associated with chemoresistance.[@R3] In our study, we also observed a higher proportion of women, a higher number of metastatic sites and locally advanced tumours among patients with right-sided tumours.

Our data also suggest that poorer efficacy outcomes might be achieved with EGFR-I in patients with right-sided tumours, questioning their value in this population. Similarly, this observation has been reported in several other studies.[@R1]

Recently, a study analysing an extensive biomarker panel revealed that the primary tumour side's association with OS and PFS outcomes in patients receiving EGFR-I did not remain significant after multivariate analysis, suggesting that mutations in *BRAF* and *NRAS*, molecular subtypes and tumour methylation may provide a biological explanation for the association with anatomical location.[@R24]

A predictive effect of tumour sidedness has been reported in several analyses, with improved results in patients with *RAS*-wt mCRC and left-sided primary tumours treated with EGFR-I as compared with those treated with chemotherapy alone or in combination with bevacizumab. In the meantime, the optimal treatment for patients with right-sided primary tumours is yet to be defined.[@R1] Despite several molecular and genetic differences having been described between them,[@R12] we observed similar survival outcomes when patients with rectum primary tumour location were grouped individually, compared with descending and sigmoid colon tumours, and these results are aligned with others.[@R4] Loupakis *et al* [@R3] found similar survival functions in their retrospective analyses of the AVF2107g and NO16966 studies. As herein observed, the ORR was found to be higher in patients with left-sided colon tumours than in patients with rectal tumours (49% vs 36%, p=0.019 in AVF2107g; and 55% vs 45% in NO16966, respectively, p=0.005).

In conclusion, the observed results, although limited by their retrospective nature and the study design, are aligned with previous works regarding the prognostic or predictive value of primary tumour sidedness in patients with *RAS*-wt mCRC treated with first-line EGFR-I plus chemotherapy. The benefit, if any, of EGFR-I in right-sided tumours remains controversial.
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